Novel covalent modification of human anaplastic lymphoma kinase (ALK) and potentiation of crizotinib-mediated inhibition of ALK activity by BNP7787

Novel covalent modification of human anaplastic lymphoma kinase (ALK) and potentiation of crizotinib-mediated inhibition of ALK activity by BNP7787

Aulma R Parker,1 Pavankumar N Petluru,1 Vicki L Nienaber,2 Min Zhao,1 Philippe Y Ayala,1 John Badger,2 Barbara Chie-Leon,2 Vandana Sridhar,2 Cheyenne Logan,2 Harry Kochat,1 Frederick H Hausheer1 1BioNumerik Pharmaceuticals, Inc., San Antonio, TX, USA; 2Zenobia Therapeutics, Inc., La Jolla, CA, USA...

Full description

Bibliographic Details
Main Authors: Parker AR, Petluru PN, Nienaber VL, Zhao M, Ayala PY, Badger J, Chie-Leon B, Sridhar V, Logan C, Kochat H, Hausheer FH
Format: Article
Language:English
Published: Dove Medical Press 2015-02-01
Series:OncoTargets and Therapy
Online Access:http://www.dovepress.com/novel-covalent-modification-of-human-anaplastic-lymphoma-kinase-alk-an-peer-reviewed-article-OTT

Internet

http://www.dovepress.com/novel-covalent-modification-of-human-anaplastic-lymphoma-kinase-alk-an-peer-reviewed-article-OTT

Similar Items